Home
Clinical Trials
Treatment of Anemia in Patien...

Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

Last Updated: 2011-04-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2004-02-29

Study Completion Date

2004-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the effectiveness of different doses of epoetin alfa for treating anemia in patients who have cancer; or patients who no longer have any signs of cancer, but remain anemic as a result of their treatment. These patients should not be currently receiving chemotherapy or radiotherapy. A subject's participation in the study will last approximately 6 months. Subjects will receive weekly doses of epoetin alfa or placebo. Their hemoglobin will be tested every week.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

NCT00083434

Anemia Cancer

TERMINATED PHASE3

A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy

NCT00283465

Anemia Neoplasm

COMPLETED PHASE4

Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy

NCT00270127

Anemia Cancer Neoplasm

COMPLETED PHASE3

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

NCT00003600

Anemia Breast Cancer Chronic Myeloproliferative Disorders +8 more

COMPLETED PHASE3

Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

NCT00255749

Anemia Leukemia Lymphoma +4 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

epoetin alfa

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body weight \>/=99 lbs
* ECOG 0-2
* Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy
* Screening hemoglobin level of \</=11.0 g/dL for men or \</=10.0 for women

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers